ATE444750T1 - Neurorestauration mit r(+) pramipexol - Google Patents

Neurorestauration mit r(+) pramipexol

Info

Publication number
ATE444750T1
ATE444750T1 AT06801521T AT06801521T ATE444750T1 AT E444750 T1 ATE444750 T1 AT E444750T1 AT 06801521 T AT06801521 T AT 06801521T AT 06801521 T AT06801521 T AT 06801521T AT E444750 T1 ATE444750 T1 AT E444750T1
Authority
AT
Austria
Prior art keywords
daily
pramipexole
disorders
disease
day
Prior art date
Application number
AT06801521T
Other languages
German (de)
English (en)
Inventor
James Bennett
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE444750T1 publication Critical patent/ATE444750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06801521T 2005-08-15 2006-08-15 Neurorestauration mit r(+) pramipexol ATE444750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70821305P 2005-08-15 2005-08-15
PCT/US2006/031831 WO2007022182A1 (en) 2005-08-15 2006-08-15 Neurorestoration with r(+) pramipexole

Publications (1)

Publication Number Publication Date
ATE444750T1 true ATE444750T1 (de) 2009-10-15

Family

ID=37428609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06801521T ATE444750T1 (de) 2005-08-15 2006-08-15 Neurorestauration mit r(+) pramipexol

Country Status (10)

Country Link
US (3) US20080234338A1 (enExample)
EP (1) EP1917014B1 (enExample)
JP (2) JP2009504748A (enExample)
AT (1) ATE444750T1 (enExample)
AU (1) AU2006279643B2 (enExample)
CA (1) CA2619217A1 (enExample)
DE (1) DE602006009670D1 (enExample)
ES (1) ES2334061T3 (enExample)
IL (1) IL189512A (enExample)
WO (1) WO2007022182A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246053B1 (en) * 2001-12-11 2013-09-18 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
BRPI0513848A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de pélete de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável deste, método para fabricação da mesma e uso desta
PH12012501282A1 (en) 2004-08-13 2019-03-22 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
EP2497472A1 (en) * 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and their pharmaceutical compositions
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010513316A (ja) * 2006-12-14 2010-04-30 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソール組成物およびその使用法
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
EP2136638A4 (en) * 2007-03-14 2010-05-12 Knopp Neurosciences Inc MODIFIED RELEASE FORMULATIONS OF (6R) -4,5,6,7-TETRAHYDRO-N6-PROPYL-2,6-BENZOTHIAZOLE DIAMINE AND METHODS OF USE THEREOF
US20100130569A1 (en) * 2007-05-11 2010-05-27 Saten Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
AU2010234244A1 (en) * 2009-04-09 2011-10-13 Purdue Pharma Once-daily oral IR/CR pramipexole formulation
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
WO2016194015A2 (en) * 2015-06-04 2016-12-08 Chiarugi Alberto Use of r(+)-pramipexole (dexpramipexole) for the treatment of cerebral ischemia of the focal type
CN110662537A (zh) * 2017-03-27 2020-01-07 才思治疗公司 用于治疗共核蛋白病的组合物和方法
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
CA2235747C (en) * 1995-10-26 2006-01-03 Sanofi Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
CA2653839A1 (en) * 1998-11-02 2000-05-11 John G. Devane Multiparticulate modified release composition
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
EP2246053B1 (en) * 2001-12-11 2013-09-18 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003077897A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
ATE499100T1 (de) * 2003-03-31 2011-03-15 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
BRPI0513848A (pt) * 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de pélete de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável deste, método para fabricação da mesma e uso desta
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol

Also Published As

Publication number Publication date
IL189512A0 (en) 2011-08-01
US20080234338A1 (en) 2008-09-25
AU2006279643A1 (en) 2007-02-22
IL189512A (en) 2013-03-24
WO2007022182A1 (en) 2007-02-22
AU2006279643B2 (en) 2010-06-17
EP1917014B1 (en) 2009-10-07
US20110218222A1 (en) 2011-09-08
DE602006009670D1 (de) 2009-11-19
US20130116292A1 (en) 2013-05-09
JP2013014629A (ja) 2013-01-24
JP2009504748A (ja) 2009-02-05
EP1917014A1 (en) 2008-05-07
CA2619217A1 (en) 2007-02-22
ES2334061T3 (es) 2010-03-04

Similar Documents

Publication Publication Date Title
IL189512A0 (en) Neurorestoration with r(+)pramipexole
Papa et al. Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
EP1121114B1 (en) Use of gaba analogs for the manufacture of a medicament for the treatment of mania and bipolar disorders
RU2009126742A (ru) Композиции и способы применения (r)-прамипексола
JP2009504748A5 (enExample)
FR2798065B1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
JPH0216284B2 (enExample)
CA2215923C (en) A method of treatment of mania and bipolar disorder
JP2016521755A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2016505050A5 (enExample)
JP3942207B2 (ja) うつ性症状改善剤
JP2016528171A5 (enExample)
EP0207011A2 (en) Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism
Sukhov et al. Long-term intranasal insulin administration improves spatial memory in male rats with prolonged type 1 diabetes mellitus and in healthy rats
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
US20100168191A1 (en) Pharmaceutical formulation comprising pramipexole
US20220287994A1 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
US5229394A (en) Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
Gupta et al. Levosulpiride: A review
EP3319603B1 (en) Use of methylphenidate for the treatment of gait and limb impairment secondary to pre-frontal cortex processing disorder
Buffum et al. Overdose of 2.3 grams of intravenous methamphetamine: case, analysis and patient perspective
JP5163986B2 (ja) フェニル酪酸ナトリウムを使用する、薬物依存症又はアルコール依存症或いは躁うつ病の予防又は治療のための医薬組成物
DE602007004018D1 (de) Imidazolcarbonsäurealkylester-haltiges Medikament zur Behandlung neurodegenerativer Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties